Drugs for the Treatment of Zika Virus Infection

Jean A. Bernatchez, Lana T. Tran, Jerry Li, Yepeng Luan, Jair L. Siqueira-Neto, Rongshi Li

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

Zika virus is an emerging flavivirus that causes the neurodevelopmental congenital Zika syndrome and that has been linked to the neuroinflammatory Guillain-Barré syndrome. The absence of a vaccine or a clinically approved drug to treat the disease combined with the likelihood that another outbreak will occur in the future defines an unmet medical need. Several promising drug candidate molecules have been reported via repurposing studies, high-throughput compound library screening, and de novo design in the short span of a few years. Intense research activity in this area has occurred in response to the World Health Organization declaration of a Public Health Emergency of International Concern on February 1, 2016. In this Perspective, the authors review the emergence of Zika virus, the biology of its replication, targets for therapeutic intervention, target product profile, and current drug development initiatives.

Original languageEnglish (US)
Pages (from-to)470-489
Number of pages20
JournalJournal of Medicinal Chemistry
Volume63
Issue number2
DOIs
StatePublished - Jan 23 2020

    Fingerprint

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Bernatchez, J. A., Tran, L. T., Li, J., Luan, Y., Siqueira-Neto, J. L., & Li, R. (2020). Drugs for the Treatment of Zika Virus Infection. Journal of Medicinal Chemistry, 63(2), 470-489. https://doi.org/10.1021/acs.jmedchem.9b00775